Sayenko Kharenko acted as a legal counsel on obtaining merger clearance for the acquisition of Ferrosan’s consumer healthcare business by Pfizer Inc.
Sayenko Kharenko antitrust team has provided legal assistance in merger clearance with the Antimonopoly Committee of Ukraine (the "AMC") for USD 686 million acquisition by Pfizer Inc. ("Pfizer"), a US-based pharmaceutical manufacturer, of Ferrosan's consumer healthcare business ("FCH"), based in Denmark.
This transaction gave the opportunity for Pfizer to diversify its investment portfolio via participation in a high growth company and allowed FCH to expand its product offering using Pfizer's global footprint and continue improving and innovating its products portfolio.
Based in Copenhagen, Ferrosan is an innovative and long-established consumer healthcare company in the Nordic region with a portfolio of leading brands. Since 1920, Ferrosan has grown to serve a broader market including Russia, the Ukraine, Poland, Turkey and many countries throughout Central and Eastern Europe.
Pfizer, the world's largest research-based pharmaceutical company, discovers, develops, manufactures, and markets leading prescription medicines for humans and animals and many of the world's best-known consumer brands.
After the review of the proposed transaction, the AMC concluded that its implementation neither poses threats to competition nor significantly limits competition on any product market in Ukraine.
Sayenko Kharenko competition team for the current transaction included counsel Dmitry Taranyk and associate Maksym Nazarenko.